| 开盘价:-- | 最高价:-- | 最低价:-- | 52周最高价:-- | 52周最低价:-- |
| 成交量:-- | 平均成交量:-- | 市值:-- | 市盈率:-- | 预期市盈率:-- |
| 每股收益:-- | 贝塔系数:-- | 股息:-- | 收益率:-- | 总股本:-- |
| 证券代码:etnb | 公司名称:89bio, Inc. | 公司中文简称: |
| 公司简介： 89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA. |
||
| 公司网站： http://www.89bio.com |
||
| 公司地址： 142 Sansome Street 2nd floor San Francisco |
||